CN1660078A - 岩白菜素及复方岩白菜素的口腔崩解片及其制备工艺 - Google Patents
岩白菜素及复方岩白菜素的口腔崩解片及其制备工艺 Download PDFInfo
- Publication number
- CN1660078A CN1660078A CN 200410093147 CN200410093147A CN1660078A CN 1660078 A CN1660078 A CN 1660078A CN 200410093147 CN200410093147 CN 200410093147 CN 200410093147 A CN200410093147 A CN 200410093147A CN 1660078 A CN1660078 A CN 1660078A
- Authority
- CN
- China
- Prior art keywords
- bergeninum
- preparation
- sodium
- lactose
- essence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YWJXCIXBAKGUKZ-HJJNZUOJSA-N Bergenin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]2C3=C(O)C(OC)=C(O)C=C3C(=O)O[C@@H]21 YWJXCIXBAKGUKZ-HJJNZUOJSA-N 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 21
- 150000001875 compounds Chemical class 0.000 title claims description 6
- XULPLJSODQQHPH-UHFFFAOYSA-N Bergenin Natural products OCC1OC2C(OC(=O)c3cc(O)c(CO)c(O)c23)C(O)C1O XULPLJSODQQHPH-UHFFFAOYSA-N 0.000 title abstract 4
- 239000011248 coating agent Substances 0.000 claims abstract description 21
- 238000000576 coating method Methods 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000000945 filler Substances 0.000 claims abstract description 8
- 239000000314 lubricant Substances 0.000 claims abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 23
- 210000000214 mouth Anatomy 0.000 claims description 20
- 241000208838 Asteraceae Species 0.000 claims description 16
- 239000000594 mannitol Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 9
- -1 hydroxypropyl Chemical group 0.000 claims description 9
- 230000000873 masking effect Effects 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 235000015165 citric acid Nutrition 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 235000010443 alginic acid Nutrition 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 7
- 239000000605 aspartame Substances 0.000 claims description 7
- 229960003438 aspartame Drugs 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 229920000609 methyl cellulose Polymers 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 6
- 230000000954 anitussive effect Effects 0.000 claims description 6
- 239000000043 antiallergic agent Substances 0.000 claims description 6
- 229940124584 antitussives Drugs 0.000 claims description 6
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 208000026435 phlegm Diseases 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000811 xylitol Substances 0.000 claims description 6
- 235000010447 xylitol Nutrition 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 6
- 229960002675 xylitol Drugs 0.000 claims description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 235000010489 acacia gum Nutrition 0.000 claims description 5
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 229940072056 alginate Drugs 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 4
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- 206010044302 Tracheitis Diseases 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000000686 essence Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 241000207199 Citrus Species 0.000 claims description 3
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 3
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 3
- 102100031013 Transgelin Human genes 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 235000020971 citrus fruits Nutrition 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 3
- 229960000511 lactulose Drugs 0.000 claims description 3
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 244000099147 Ananas comosus Species 0.000 claims description 2
- 235000007119 Ananas comosus Nutrition 0.000 claims description 2
- 101100273639 Carassius auratus ccna1 gene Proteins 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 244000147568 Laurus nobilis Species 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 240000008790 Musa x paradisiaca Species 0.000 claims description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 2
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000007931 coated granule Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 229940109275 cyclamate Drugs 0.000 claims description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 2
- 238000007907 direct compression Methods 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940014259 gelatin Drugs 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 150000004804 polysaccharides Chemical class 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000000429 sodium aluminium silicate Substances 0.000 claims description 2
- 235000012217 sodium aluminium silicate Nutrition 0.000 claims description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229960001462 sodium cyclamate Drugs 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 2
- 235000012141 vanillin Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 229960002737 fructose Drugs 0.000 claims 3
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 claims 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004574 azelastine Drugs 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 229960003291 chlorphenamine Drugs 0.000 claims 1
- 229960002881 clemastine Drugs 0.000 claims 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- 229960001271 desloratadine Drugs 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 229960001971 ebastine Drugs 0.000 claims 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims 1
- 229960000325 emedastine Drugs 0.000 claims 1
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 claims 1
- 229960003592 fexofenadine Drugs 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 229960001120 levocabastine Drugs 0.000 claims 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims 1
- 229960003088 loratadine Drugs 0.000 claims 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 229960001144 mizolastine Drugs 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 229960003910 promethazine Drugs 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 229960000351 terfenadine Drugs 0.000 claims 1
- 229960003223 tripelennamine Drugs 0.000 claims 1
- 206010011224 Cough Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 abstract description 2
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229960004106 citric acid Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 241000220151 Saxifragaceae Species 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000003151 isocoumarinyl group Chemical class C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种具有镇咳、祛痰、抗炎、解热、抗病毒等功效,并能全方位治疗慢性气管炎的岩白菜素及复方岩白菜素的口腔崩解片及其制备工艺。以岩白菜素或岩白菜素和抗过敏药的复方为原料,填充剂、崩解剂、矫味剂、助流剂、润滑剂等为辅料,根据不同情况可使用粘合剂或包衣材料,也可酌情加入适量泡腾剂,再经过特定的制备方法制备,采用压片机压片即得。本发明的口腔崩解片脆碎度良好,崩解迅速,口感好,无砂砾感,不需要特殊的生产条件;具有生产成本低,携带、储藏、运输和服用方便等特点;特别之处是可以在无水条件下服用并快速起效,从而改善患者的依从性,提高药物的疗效。
Description
技术领域
本发明涉及一种具有镇咳、祛痰、抗炎、解热、抗病毒等功效,并能全方位治疗慢性气管炎的岩白菜素及复方岩白菜素的口腔崩解片及其制备工艺。
背景技术
岩白菜素是从新疆虎耳草科植物厚叶岩白菜提炼精制得到的异香豆精类化合物,研究表明,岩白菜素具有如下功效:
①强效镇咳:镇咳强度约相当于可待因的四分之一,迅速止咳。并且对咳嗽中枢有选择性抑制作用,而对其它中枢无明显的抑制作用,避免了吗啡类镇咳药中枢抑制的副作用。
②强效祛痰:其作用强度与同等剂量的桔梗相当,驱除支气管病理分泌物,保持呼吸道通畅。消除致病微生物的寄生环境。
③抗炎作用:对炎症早期的血管通透性亢进、渗出和水肿有显著抑制作用,以及对增殖期炎症也有很好的抑制作用。有利于缓解慢性支气管炎的临床症状。
解热作用:对家兔由耳缘静脉注射霍乱、伤寒、副伤寒、甲忆菌苗、破伤风类毒素混合制剂引起的发热有较强的解热作用。
④抗病毒作用:不仅能抑灭DNA病毒,而且能抑制RNA病毒。灭活病毒后的细胞仍能继续分裂传代,说明岩白菜素抑灭病毒有效而不伤害病毒所寄宿的细胞。
⑤促进病变组织恢复作用:以二氧化硫熏气法制造大鼠慢性气管炎模型,以岩白菜素治疗10天,结果表明治疗组大鼠气管的杯状细胞减少(显示有命名粘量减少的祛痰作用),炎细胞浸润减轻,肺气肿及肺萎陷程度也减轻,解决了慢性支气管炎的组织学改变的治疗问题。
岩白菜素具有显著的强效镇咳、祛痰、抗炎、解热、抗病毒生物活性,促进病变组织恢复等复合作用,具有全方位慢性气管炎的作用。岩白菜素的开发成功是我国发掘传统中医药的重要成果。抗过敏药具有较强的组胺H1受体阻断作用,可减轻过敏引起的呼吸道其他症状,两药配合共同组成治疗咳喘病的优秀处方。解决了当今治疗慢性支气管炎药和疗效单一的问题,提升了治疗效果,对慢性支气管炎具有良好的镇咳、祛痰作用
现有的岩白菜素及复方岩白菜素制剂的剂型主要是普通片。普通片服用时需要大量的水送下,这使得许多老年人、婴幼儿或者吞咽困难、取水不便的患者和咳嗽及哮喘患者难以服用。因此,有必要制备服用更加方便的剂型以满足临床治疗和家庭使用的多种需要。
发明内容
本发明的目的在于改进现有的岩白菜素和复方岩白菜素在口服剂型方面的不足,向广大患者和医务工作者提供一种服用方便、吸收起效快、生物利用度高的岩白菜素及复方岩白菜素口腔崩解片制剂。本发明涉及服用时不必饮水、在口腔中仅需几十秒即可迅速崩解或溶解、随唾液下咽即可完成服药的岩白菜素及复方岩白菜素口腔崩解片及其制备方法。
一、处方
本发明所述及的岩白菜素及复方岩白菜素的口腔崩解片,包括药物原料在内,共需要以下9类原、辅材料,其中:不作包衣处理时,则不使用包衣材料,泡腾剂为酌情可选用辅料,也可不用。
岩白菜素或复方岩白菜素和抗过敏药所组成的复方、填充剂、崩解剂、矫味剂、助流剂、润滑剂等原辅料,根据情况还可以添加粘合剂、泡腾剂或包衣材料,以适当的配比,经特定的方法制备而成。其特征在于其处方组成如下:岩白菜素或岩白菜素和抗过敏药所组成的复方(5-70)%,粘合剂(0-5)%,填充剂(10-80)%,崩解剂(2-35)%,矫味剂(1-40)%,包衣材料(0-40)%,泡腾剂(0-30)%,助流剂(0.01-5)%,润滑剂(0.3-3)%。
其中:
粘合剂包括但不仅限于淀粉、预胶化淀粉、糊精、麦芽糖糊精、蔗糖、阿拉伯胶、明胶、甲基纤维素、羧甲基纤维素、乙基纤维素、聚乙烯醇、聚乙二醇、聚乙烯吡咯烷酮(PVP)、海藻酸及海藻酸盐、黄原胶、羟丙基纤维素和羟丙基甲基纤维素(HPMC),可单独使用,也可组合使用。
填充剂包括但不仅限于甘露醇(粒状或粉状)、木糖醇、山梨醇、麦芽糖、赤蘚醇、微晶纤维素、PROSOLVSMCC、聚合糖(EMDEX)、偶合糖、葡萄糖、乳糖、蔗糖、糊精和淀粉等,可以单独使用,也可以组合应用,用量通常为(10-80)%。
崩解剂包括但不仅限于交联聚乙烯吡咯烷酮(PVPP)、羧甲基淀粉钠(CMS-Na)、低取代羟丙基甲基纤维素(L-HPC)、交联羧甲基纤维素钠(CCNa)和大豆多糖(EMCOSOY)等,可单独使用,也可组合使用。
矫味剂包括但不仅限于甘露醇、木糖醇、乳糖、果糖、蔗糖、蛋白糖、麦芽糖醇、山梨醇、甘露醇、还原淀粉糖、木糖醇、还原巴糖、赤藓醇、异构化乳糖(乳果糖)、还原乳糖(乳糖醇)、明胶、甘草甜素、环己氨基磺酸钠、阿斯巴甜、甜菊甙、甜蜜素、香蕉香精、菠萝香精、香兰素、香橙香精、桔子香精、薄荷香精、人参香精、草莓香精、枸橼酸、柠檬酸等,可单独使用,也可组合使用。
包衣材料包括但不仅限于明胶、阿拉伯胶、海藻酸盐、壳聚糖、羧甲基纤维素盐、醋酸纤维素酞酸酯、乙基纤维素、甲基纤维素、羟丙甲纤维素、丙烯酸树脂类(国产丙烯酸树脂I、II、III、IV,Eudragit系列)、聚乙烯醇、聚乙烯吡咯烷酮、聚乙二醇等,可单独使用,也可组合使用。
助流剂包括但不仅限于微粉硅胶、滑石粉、Cab-O-sil、Arosil、水合硅铝酸钠等,可单独使用,也可组合使用。
润滑剂包括但不仅限于硬脂酸镁、硬脂酸钙、硬脂酸锌、单硬脂酸甘油脂、聚乙二醇、氢化植物油、硬脂富马酸钠、聚氧乙烯单硬脂酸酯、单月桂蔗糖酸酯、月桂醇硫酸钠、月桂醇硫酸镁、十二烷基硫酸镁和滑石粉等,可单独使用,也可组合使用。
泡腾剂包括但不仅限于苹果酸、柠檬酸或枸橼酸与碳酸氢钠或碳酸钠的混合物。
二、制备方法
本发明所述及的复方岩白菜素口腔崩解片,其制备方法为直接压片法,具有制备常规片剂的生产厂家均可采用。
岩白菜素味苦,本发明可采用二种不同方法进行矫味或掩味:①采用矫味剂直接矫味;②预先将岩白菜素进行粉末包衣以掩味。
具体制备方法如下:
第一步 复方岩白菜素的预处理方法:
①直接矫味法——本法对原料和/或部分辅料进行制粒或不作处理,直接进入第二步;
②包衣掩味法——取所选定的包衣材料,用与之相适应的溶媒溶解并稀释至适当浓度备用,再将原料置于沸腾床中使沸腾,然后以适当速度喷入上述溶液进行包衣,得包衣颗粒,干燥后过筛备用;
第二步 将矫味剂与经第一步处理后的原料颗粒按量称取,并混合均匀备用;
第三步 将填充剂、崩解剂、泡腾剂、助流剂按量称取并混合均匀,再与经第二步所得之物料混合使均匀,加入润滑剂混匀备用;
第四步 所得物料经中间体检测,确定片重后,送入压片机压片即得。
有益效果
片剂是一种传统剂型,因其质量稳定、剂量准确、服用、携带方便、机械化程度高、生产成本低而成为目前最常用的剂型之一,但因片剂加压成型,崩解较慢、生物利用度较低,且部分患者吞服较为困难,因而片剂的推广使用在一定程度上受到限制。为此口服固体速释制剂成为近年新药研发的一个热点,特别是口腔崩解片,因其服用方便、起效快、生物利用度高、口感好而成为片剂开发的重点。
口腔崩解片是指不需用水或只需少量水,无需咀嚼,片剂置于舌面,遇唾液后迅速崩解,或借吞咽动力,药物即可入胃起效的片剂。口腔崩解片的特点是吸收快、生物利用度高,肠道残留少,副作用低,避免肝脏首过效应等。
据《口腔崩解片的剂型特点和质量控制会议纪要》的要求,口腔崩解片比滴丸和普通片的崩解速度有本质的飞跃,口腔崩解片的崩解一般在30秒以内,最多不超过1分钟。
具体实施方式
为了更好的说明本发明所述复方岩白菜素口腔崩解片的制备方法,结合直接矫味法、粉末包衣掩味法和泡腾剂矫味法分别举一个实施例。所举的实施例是为了进一步说明本发明,但不以任何方式限定本发明。
实施例一 直接矫味法——岩白菜素口腔崩解片
一.处方
1.原 料——岩白菜素 125.0g;
2.粘合剂——羟丙基甲基纤维素 2.0g;
3.填充剂——甘露醇 168.0g;
微晶纤维素 20.0g;
4.矫味剂——阿斯巴甜 3.5g;
薄荷香精 3.5g;
5.崩解剂——交联聚乙烯吡咯烷酮 10.5g;
交联羧甲基纤维素钠 10.5g;
6.助流剂——微粉硅胶 3.5g;
7.润滑剂——硬脂酸镁 3.5g。
总计350g,共制成1000片。
二.制备方法
1)取岩白菜素原料和部分甘露醇粉混合后粉碎,备用;
2)将羟丙基甲基纤维素(优选3至50厘泊)用适量的乙醇溶液溶解备用;
3)用步骤2)所配制的粘合剂溶液对步骤1)的物料进行制粒,干燥,过26目筛,备用;
4)将微粉硅胶、薄荷香精、微晶纤维素和阿斯巴甜,过筛,混合均匀,再加入步骤3)的颗粒,混合均匀,备用;
5)取剩余量的甘露醇(粒状)、交联聚乙烯吡咯烷酮和交联羧甲基纤维素钠混合均匀,再加入步骤4)的物料,混合均匀,最后加入硬脂酸镁混合均匀;
6)中间体检测,确定片重后,送入压片机压片即得。
实施例二 包衣掩味法——复方岩白菜素口腔崩解片
一.处方
1.原 料——岩白菜素 125.0g;
马来酸氯苯那敏 2.0g;
2.包衣材料——乙基纤维素 18.7g;
甲基纤维素 6.3g;
3.填 充 剂——甘露醇 147.0g;
微晶纤维素 17.5g;
4.矫 味 剂——阿斯巴甜 2.0g;
薄荷香精 3.5g;
5.崩 解 剂——交联聚乙烯吡咯烷酮 9.0g;
交联羧甲基纤维素钠 9.0g;
6.助 流 剂——微粉硅胶 6.5g;
7.润 滑 剂——硬脂酸镁 3.5g。
总计350g,共制成1000片。
二.制备方法
1)取马来酸氯苯那敏,用递加稀释法和岩白菜素混合,备用;
2)将乙基纤维素和甲基纤维素用适量的乙醇溶液溶解,备用;
3)将步骤1)的物料置于流化床中,用步骤2)所配制的粘合剂溶液进行包衣,干燥,过26目筛,备用;
4)将微粉硅胶、薄荷香精、微晶纤维素和阿斯巴甜,过筛,混合均匀,再加入步骤3)的颗粒,混合均匀,备用;
5)取甘露醇(粒状)、交联聚乙烯吡咯烷酮和交联羧甲基纤维素钠混合均匀,再加入步骤4)的物料,混合均匀,最后加入硬脂酸镁混合均匀;
6)中间体检测,确定片重后,送入压片机压片即得。
实施例三 泡腾剂矫味法——复方岩白菜素口腔崩解片
一.处方
1.原 料——岩白菜素 125.0g;
马来酸氯苯那敏 2.0g;
2.粘合剂——羟丙基甲基纤维素 5.0g;
3.泡腾剂——无水柠檬酸 33.0g;
碳酸氢钠 30.0g;
4.填充剂——甘露醇 148.0g;
PROSOLVSMCC 16.5g;
5.矫味剂——阿斯巴甜 2.0g;
香橙香精 3.5g;
6.崩解剂——交联羧甲基纤维素钠 15.0g;
低取代羟丙基纤维素 12.0g;
7.助流剂——微粉硅胶 4.0g;
8.润滑剂——硬脂酸镁 4.0g。
总计400g,共制成1000片。
二.制备方法
1)取马来酸氯苯那敏,用递加稀释法和岩白菜素混合,备用;
2)将羟丙基甲基纤维素(优选3至50厘泊)用适量的乙醇溶液溶解,备用;
3)取无水柠檬酸,粉碎后和步骤1)的物料及部分甘露醇粉混合后用步骤2)部分粘合剂溶液用流化床制粒,干燥后过筛,备用;
4)取碳酸氢钠粉碎后与剩余的甘露醇粉混合均匀,以剩余的粘合剂溶液用流化床制粒,过筛,备用;
5)将其余所有的辅料分别过40目筛后混合均匀,再加入已制粒的颗粒,混合均匀,备用;
6)中间体含量检测,确定片重后,送入压片机压片即得。
Claims (10)
1.一种具有镇咳、祛痰、抗炎、解热、抗病毒等功效,并能全方位治疗慢性气管炎的岩白菜素及复方岩白菜素的口腔崩解片,由岩白菜素或岩白菜素和抗过敏药所组成的复方原料、填充剂、崩解剂、矫味剂、助流剂、润滑剂等原辅料,根据情况还可以添加粘合剂、泡腾剂或包衣材料,以适当的配比,经特定的方法制备而成。其特征在于其处方组成如下:岩白菜素或岩白菜素和抗过敏药所组成的复方原料(5-70)%,粘合剂(0-5)%,填充剂(10-80)%,崩解剂(2-35)%,矫味剂(1-40)%,包衣材料(0-40)%,泡腾剂(0-30)%,助流剂(0.01-5)%,润滑剂(0.3-3)%。
2.按照权利要求1所述及的所述及的抗过敏药,包括但不仅限于异丙嗪、氯苯那敏、色甘酸钠、曲吡那敏、特非那定、阿司咪唑、氮斯汀、西替利嗪、依巴斯汀、左卡巴斯汀、依美斯汀、咪唑斯汀、氯马斯汀、非索非那定、氯雷他定、地氯雷他定等及其各种形式的盐类,可单独使用,也可组合使用;优选使用马来酸氯苯那敏。
3.按照权利要求1所述及的所述及的各种辅料,其特征在于各自的选择种类如下:
粘合剂——包括但不仅限于淀粉、预胶化淀粉、糊精、麦芽糖糊精、蔗糖、阿拉伯胶、明胶、甲基纤维素、羧甲基纤维素、乙基纤维素、聚乙烯醇、聚乙二醇、聚乙烯吡咯烷酮(PVP)、海藻酸及海藻酸盐、黄原胶、羟丙基纤维素和羟丙基甲基纤维素(HPMC),可单独使用,也可组合使用。
填充剂——包括但不仅限于微晶纤维素、PROSOLVSMCC、甘露醇(粒状或粉状)、木糖醇、山梨醇、麦芽糖(醇)、赤蘚醇、聚合糖(EMDEX)、偶合糖、葡萄糖、蔗糖、果糖、低聚糖、左旋糖、乳糖、异构化乳糖(乳果糖)、还原乳糖(乳糖醇)、糊精、还原淀粉糖、还原巴糖和淀粉等,可以单独使用,也可以组合应用,用量通常为(10-80)%。
崩解剂——包括但不仅限于交联聚乙烯吡咯烷酮(PVPP)、羧甲基淀粉钠(CMS-Na)、低取代羟丙基甲基纤维素(L-HPC)、交联羧甲基纤维素钠(CCNa)和大豆多糖(EMCOSOY)等,可单独使用,也可组合使用。
矫味剂——包括但不仅限于甘露醇、木糖醇、乳糖、果糖、蔗糖、蛋白糖、麦芽糖醇、山梨醇、甘露醇、还原淀粉糖、木糖醇、还原巴糖、赤藓醇、异构化乳糖(乳果糖)、还原乳糖(乳糖醇)、明胶、甘草甜素、环己氨基磺酸钠、阿斯巴甜、甜菊甙、甜蜜素、香蕉香精、菠萝香精、香兰素、香橙香精、桔子香精、薄荷香精、人参香精、草莓香精、枸橼酸、柠檬酸等,可单独使用,也可组合使用。
包衣材料——包括但不仅限于明胶、阿拉伯胶、海藻酸盐、壳聚糖、羧甲基纤维素盐、醋酸纤维素酞酸酯、乙基纤维素、甲基纤维素、羟丙甲纤维素、丙烯酸树脂类(国产丙烯酸树脂I、II、III、IV,Eudragit系列)、聚乙烯醇、聚乙烯吡咯烷酮、聚乙二醇等,可单独使用,也可组合使用。
助流剂——包括但不仅限于微粉硅胶、滑石粉、Cab-O-sil、Arosil、水合硅铝酸钠等,可单独使用,也可组合使用。
润滑剂——包括但不仅限于硬脂酸镁、硬脂酸钙、硬脂酸锌、单硬脂酸甘油脂、聚乙二醇、氢化植物油、硬脂富马酸钠、聚氧乙烯单硬脂酸酯、单月桂蔗糖酸酯、月桂醇硫酸钠、月桂醇硫酸镁、十二烷基硫酸镁和滑石粉等,可单独使用,也可组合使用。
4.一种用于权利要求1所述及的岩白菜素或复方岩白菜素口腔崩解片的制备方法,其特征在于由以下步骤组成:
第一步 原料的预处理,可采取如下两种方法:
(1)直接矫味法——本法可对原料进行制粒或不作处理,直接进入第二步;
(2)包衣掩味法——取所选定的包衣材料,用与之相适应的溶媒溶解并稀释至适当浓度备用,再取原料置于沸腾床中使沸腾,然后以适当速度喷入上述溶液进行粉末包衣,得包衣颗粒,干燥后过筛备用;
第二步 将矫味剂与经第一步掩味处理后的原料颗粒按量称取,并混合均匀备用;
第三步 将填充剂、崩解剂、泡腾剂、助流剂按量称取并混合均匀,再与经第二步所得之物料混合使均匀,加入润滑剂混匀备用;
第四步 所得物料经中间体检测,确定片重后,送入压片机压片即得。
5.按照权利要求4所述及的制备方法,其特征在于:第一步的方法(2)需要预先使用包衣材料对原料进行掩味处理。
6.按照权利要求5所述及的制备方法,其特征在于:用于掩味处理的包衣材料是明胶、阿拉伯胶、海藻酸盐、壳聚糖、羧甲基纤维素盐、醋酸纤维素酞酸酯、乙基纤维素、甲基纤维素、羟丙甲纤维素、丙烯酸树脂类(国产丙烯酸树脂I、II、III、IV,Eudragit系列)、聚乙烯醇、聚乙烯吡咯烷酮、聚乙二醇等任意一种或两种以上的混合物。
7.按照权利要求4所述及的制粒方法,其特征在于可使用干法制粒机制备,也可使用高速搅拌混合制粒机、摇摆制粒机和流化床一步制粒机制备;优选使用流化床一步制粒法。
8.按照权利要求4所述及的任何一种制备方法,其特征在于:根据情况还可加入辅料泡腾剂。
9.按照权利要求7所述及的泡腾剂,其特征在于:该辅料是苹果酸、柠檬酸或枸橼酸与碳酸氢钠或碳酸钠的混合物。
10.一种用于权利要求1所述及的岩白菜素及复方岩白菜素口腔崩解片的制备方法,其特征在于其采用直接压片法制备工艺,片剂的硬度在10至45牛顿之间,崩解时间在1-60秒内。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410093147 CN1660078A (zh) | 2004-12-17 | 2004-12-17 | 岩白菜素及复方岩白菜素的口腔崩解片及其制备工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410093147 CN1660078A (zh) | 2004-12-17 | 2004-12-17 | 岩白菜素及复方岩白菜素的口腔崩解片及其制备工艺 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1660078A true CN1660078A (zh) | 2005-08-31 |
Family
ID=35009822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410093147 Pending CN1660078A (zh) | 2004-12-17 | 2004-12-17 | 岩白菜素及复方岩白菜素的口腔崩解片及其制备工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1660078A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797253A (zh) * | 2010-03-18 | 2010-08-11 | 四川大学 | 一种岩白菜素、盐酸西替利嗪复方口服剂型 |
| CN103610713A (zh) * | 2013-12-12 | 2014-03-05 | 昆明振华制药厂有限公司 | 一种复方岩白菜素片及制备方法 |
| CN106562957A (zh) * | 2015-10-08 | 2017-04-19 | 中国科学院微生物研究所 | 化合物aj-2在制备治疗或预防流感病毒的药物中的应用 |
| WO2019077620A1 (en) * | 2017-10-16 | 2019-04-25 | Council Of Scientific & Industrial Research | FORMULATIONS WITH EXTENDED RELEASE AND GASTRIC RETENTION OF BERGENIA CILIATA |
| CN110403910A (zh) * | 2019-09-02 | 2019-11-05 | 广东九明制药有限公司 | 地氯雷他定片及其制备方法 |
-
2004
- 2004-12-17 CN CN 200410093147 patent/CN1660078A/zh active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797253A (zh) * | 2010-03-18 | 2010-08-11 | 四川大学 | 一种岩白菜素、盐酸西替利嗪复方口服剂型 |
| CN103610713A (zh) * | 2013-12-12 | 2014-03-05 | 昆明振华制药厂有限公司 | 一种复方岩白菜素片及制备方法 |
| CN103610713B (zh) * | 2013-12-12 | 2016-01-20 | 昆明振华制药厂有限公司 | 一种复方岩白菜素片及制备方法 |
| CN106562957A (zh) * | 2015-10-08 | 2017-04-19 | 中国科学院微生物研究所 | 化合物aj-2在制备治疗或预防流感病毒的药物中的应用 |
| CN106562957B (zh) * | 2015-10-08 | 2019-02-12 | 中国科学院微生物研究所 | 化合物aj-2在制备治疗或预防流感病毒的药物中的应用 |
| WO2019077620A1 (en) * | 2017-10-16 | 2019-04-25 | Council Of Scientific & Industrial Research | FORMULATIONS WITH EXTENDED RELEASE AND GASTRIC RETENTION OF BERGENIA CILIATA |
| US11446346B2 (en) * | 2017-10-16 | 2022-09-20 | Council Of Scientific & Industrial Research | Gastroretentive sustained release formulations of Bergenia ciliata |
| CN110403910A (zh) * | 2019-09-02 | 2019-11-05 | 广东九明制药有限公司 | 地氯雷他定片及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1586475A (zh) | 维生素c口腔崩解片及其制备方法 | |
| CN1237981C (zh) | 银杏叶口腔崩解片及其制备方法 | |
| CN1303989C (zh) | 葡萄糖酸锌口腔崩解片及其制备工艺 | |
| CN1660078A (zh) | 岩白菜素及复方岩白菜素的口腔崩解片及其制备工艺 | |
| CN1586483A (zh) | 西地那非及其药学上可接受的盐的口腔崩解片及其制备方法 | |
| CN1250228C (zh) | 三七总皂苷口腔崩解片及其制备方法 | |
| CN1247202C (zh) | 薯蓣皂苷口腔崩解片及其制备方法 | |
| CN1247195C (zh) | 水飞蓟宾口腔崩解片及其制备工艺 | |
| CN1297263C (zh) | 葡萄糖酸钙口腔崩解片及其制备工艺 | |
| CN1283267C (zh) | 人参茎叶总皂苷口腔崩解片制剂及其制备方法 | |
| CN1267094C (zh) | 红花黄色素口腔崩解片及其制备工艺 | |
| CN1706372A (zh) | 阿魏酸钠口腔崩解片及其制备方法 | |
| CN1586469A (zh) | 水飞蓟素口腔崩解片及其制备方法 | |
| CN1247203C (zh) | 豆腐果苷口腔崩解片及其制备方法 | |
| CN1303990C (zh) | 阿魏酸钠口腔崩解片及其制备工艺 | |
| CN1903183A (zh) | 替比夫定分散片及其制备方法 | |
| CN1263457C (zh) | 绞股蓝总皂苷口腔崩解片及其制备工艺 | |
| CN1586471A (zh) | 水飞蓟宾葡甲胺盐口腔崩解片制剂及其制法 | |
| CN1586597A (zh) | 人参口腔崩解片及其制备工艺 | |
| CN1250217C (zh) | 联苯双酯口腔崩解片及其制备工艺 | |
| CN1903208A (zh) | 阿德福韦酯口崩片药物制剂及其制备方法 | |
| CN1943561A (zh) | 普卢利沙星口腔崩解片及其制备方法 | |
| CN1296045C (zh) | 二氢麦角碱及其衍生物的口腔崩解片及其制备工艺 | |
| CN1634390A (zh) | 刺五加口腔崩解片及其制备工艺 | |
| CN1695617A (zh) | 甲磺酸氨氯地平口腔崩解片及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Hongxi Document name: Second notice of examination advice |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20050831 |